MINT

Myocardial Ischemia and Transfusion (MINT) trial

PI: Tamar Polonsky, Department of Medicine

Dates: 9/1/16 - 5/31/21
Grant #: FP066710
Funder: NHLBI, NIH

Description: Accumulating evidence from clinical trials suggests that a restrictive transfusion strategy is safe in most clinical settings. However, a low oxygen carrying capacity from moderate anemia may be deleterious in patients with cardiac ischemia. The potential for harm associated with anemia in patients with acute symptomatic coronary disease is supported by pathophysiological data that maintaining higher hemoglobin levels could benefit the ischemic heart by increasing oxygen delivery. Systematic reviews of clinical trials evaluating transfusion strategies in patients with known ischemic heart disease document the absence of high quality data, which has resulted in an ongoing controversy. The lack of high quality evidence to guide transfusions in patients with acute myocardial infarction has been cited in several major guidelines as well as by an NIH expert panel.

This multicenter trial, the Myocardial Ischemia and Transfusion (MINT) trial, randomly allocates 3500 patients with acute myocardial infarction and a hemoglobin concentration less than 10 g/dL to be treated either according to a liberal or restrictive blood transfusion strategy.

Learn more about this program here.